NeuroPace (NASDAQ:NPCE – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by insiders. Comparatively, 5.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
NeuroPace has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroPace | 1 | 1 | 6 | 0 | 2.63 |
| Envoy Medical | 1 | 0 | 1 | 0 | 2.00 |
NeuroPace presently has a consensus price target of $18.50, indicating a potential upside of 10.58%. Envoy Medical has a consensus price target of $9.50, indicating a potential upside of 1,297.88%. Given Envoy Medical’s higher probable upside, analysts plainly believe Envoy Medical is more favorable than NeuroPace.
Profitability
This table compares NeuroPace and Envoy Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroPace | -25.28% | -136.60% | -22.94% |
| Envoy Medical | -11,950.00% | N/A | -248.54% |
Valuation & Earnings
This table compares NeuroPace and Envoy Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroPace | $79.91 million | 6.97 | -$27.14 million | ($0.76) | -22.01 |
| Envoy Medical | $220,000.00 | 88.93 | -$20.80 million | ($1.41) | -0.48 |
Envoy Medical has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroPace beats Envoy Medical on 8 of the 14 factors compared between the two stocks.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
About Envoy Medical
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
